Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 2:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 1,547 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: open surgery Clear all
Completed Not applicable Interventional Results available

Open Vs Robotic-Assisted Radical Cystectomy: A Randomized Trial

NCT01157676
View directory record Official record
Conditions
Bladder Cancer Requiring Cystectomy
Interventions
Open radical cystectomy, Robotic assisted radical cystectomy, DaVinci robot
Procedure · Device
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Phoenix, Arizona • Orange, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Oct 28, 2026, 2:53 AM EDT
Withdrawn Not applicable Interventional

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

NCT01094535
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Synthetic Human Secretin
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 28, 2026, 2:53 AM EDT
Active, not recruiting Phase 1 Interventional

Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure

NCT02808208
View directory record Official record
Conditions
End Stage Renal Disease (ESRD), Vascular Access Complication
Interventions
Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC), Placebo, Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

NCT05156983
View directory record Official record
Conditions
Coagulation Disorder
Interventions
TAK-330, SOC 4F-PCC
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
13
States / cities
Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Not applicable Interventional

Radiosurgery or Open Surgery for Epilepsy Trial

NCT00860145
View directory record Official record
Conditions
Epilepsy
Interventions
radiosurgery, temporal lobectomy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
13
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 28, 2026, 2:53 AM EDT
Not listed Phase 2 Interventional

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

NCT05182866
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
ASP-1929 Photoimmunotherapy
Combination Product
Lead sponsor
Rakuten Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2024 · Synced Oct 28, 2026, 2:53 AM EDT
Terminated Not applicable Interventional Results available

ExAblate Treatment of Uterine Fibroids for Fertility Enhancement

NCT00730886
View directory record Official record
Conditions
Uterine Fibroids, With Unexplained Infertility
Interventions
ExAblate 2000, Myomectomy
Device · Procedure
Lead sponsor
InSightec
Industry
Eligibility
21 Years to 40 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Los Angeles, California • Smyrna, Georgia • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)

NCT03779841
View directory record Official record
Conditions
Post-Operative Atrial Fibrillation
Interventions
AGN-151607, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
55 Years to 90 Years
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 1 Interventional

An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection

NCT06692179
View directory record Official record
Conditions
Recurrent Clostridioides Difficile Infection, Colonic Surgery
Interventions
Orally administered preparation of fecal microbiota (MTP-101P)
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Not applicable Interventional Results available

The Safety and Effectiveness of UroLift: LIFT Pivotal Study

NCT01294150
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift System, Cystoscopy, Crossover
Device · Other
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
14
States / cities
San Diego, California • San Jose, California • Englewood, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to Autografting

NCT06223269
View directory record Official record
Conditions
Burns Degree Third, Burn (Disorder), Burn Degree Second, Thermal Burn, Wound Heal
Interventions
Skin Xenotransplant, Autograft(ing)
Drug · Procedure
Lead sponsor
XenoTherapeutics, Inc.
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • Augusta, Georgia • Portland, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 28, 2026, 2:53 AM EDT
Terminated No phase listed Observational

Cancer Treatment Decision-making in the HIV Population: an Observational Study of Physician-patient Interactions

NCT03721796
View directory record Official record
Conditions
Newly Diagnosed Cancer Patients Who Are HIV Positive and Their Treating Oncologist
Interventions
Audio recording of initial consultation and debriefing interviews.
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 21, 2023 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 2 Interventional Results available

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

NCT05549505
View directory record Official record
Conditions
Breast Cancer
Interventions
ARV-471, Anastrozole, Surgical resection of breast tumor
Drug · Procedure
Lead sponsor
Arvinas Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Los Angeles, California • Torrance, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy

NCT04136366
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
ADX-2191 (intravitreal methotrexate 0.8%), Standard surgical care procedure
Drug · Other
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 3 Interventional Results available

TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery

NCT01192022
View directory record Official record
Conditions
Hemorrhage
Interventions
TachoSil®, Surgicel® Original
Biological · Device
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
17
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Not applicable Interventional

Pivotal Study of the Velocity™ pAVF System

NCT07153939
View directory record Official record
Conditions
Chronic Kidney Disease, Hemodialysis Access, Arteriovenous Fistula, End Stage Renal Disease (ESRD)
Interventions
Velocity Percutaneous Arteriovenous Fistula
Device
Lead sponsor
Venova Medical
Industry
Eligibility
18 Years to 80 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
13
States / cities
Dothan, Alabama • Concord, California • Riverside, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy

NCT04982653
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Neoplasm, Metastatic Malignant Neoplasm in the Liver, Primary Malignant Liver Neoplasm
Interventions
Quality-of-Life Assessment, Surgical Procedure
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Cisplatin, Pemetrexed, Gemcitabine, Carboplatin, Paclitaxel, Rescue medication
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
51
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Beverly Hills, California + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Withdrawn Not applicable Interventional

Pre-operative Tumor Treating Fields in Patients With Resectable Lung Cancer

NCT06552000
View directory record Official record
Conditions
NSCLC, Non Small Cell Lung Cancer
Interventions
NovoTTF-200T System
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
22 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Completed Phase 4 Interventional

A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries

NCT06887972
View directory record Official record
Conditions
Acute Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Atlanta, Georgia • Boston, Massachusetts • Bellaire, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 28, 2026, 2:53 AM EDT
Not yet recruiting Not applicable Interventional

Study on Outcomes of Proximal Humerus Fractures

NCT07060664
View directory record Official record
Conditions
Proximal Humerus Fracture
Interventions
open reduction internal fixation, intramedullary nail, reverse total shoulder arthroplasty
Procedure
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 2 Interventional

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT04553770
View directory record Official record
Conditions
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Interventions
Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
Drug · Procedure · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 28, 2026, 2:53 AM EDT
Active, not recruiting Not applicable Interventional Results available

Apical Suspension Repair for Vault Prolapse In a Three-Arm Randomized Trial Design

NCT02676973
View directory record Official record
Conditions
Visceral Prolapse
Interventions
Open, Robotic, or Laparoscopic, Transvaginal Native Tissue Repair, Uphold™ LITE
Procedure
Lead sponsor
NICHD Pelvic Floor Disorders Network
Network
Eligibility
21 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Albuquerque, New Mexico + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 28, 2026, 2:53 AM EDT
Recruiting Phase 4 Interventional

Placement of Antibiotic Powder in Wounds During the Emergency Room

NCT03765567
View directory record Official record
Conditions
Open Fracture
Interventions
Vancomycin
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 28, 2026, 2:53 AM EDT